Abstract OBJECTIVE: To improve the compliance with subcutaneous specific immunotherapy (SCIT) by analyzing the causes of stopping SCIT in asthmatic children. METHODS: A telephone follow-up was conducted in the asthmatic children who received SCIT but did not finished the 3-year course of treatment from June 2005 to October 2010, so as to analyze the causes of stopping SCIT. RESULTS: A total of 616 asthmatic children received SCIT, and 322 (52.2%) of them stopped SCIT.A total of 127 cases (39.4%) of the 322 children received telephone follow-up. In the 127 children, 53 (41.8%) stopped the SCIT for the reason of bad effecacy, 29 (22.8%) for remission of asthma,12 (9.4%) for expensive fees, 10 (7.9%) for complex process of treatment, 10 (7.9%) for adverse reaction, 9 (7.1%) for long distance from the hospital, and 4 (3.1%) for having no time for treatment. And 69 (54.3%) of them stopped SCIT in the first year, 28 (22.1%) in the second year, and 30 (23.6%) in the third year. Currently, 85 cases (66.9%) of the 127 asthmatic children were up to the control level, and the other 42 cases were not. There was significant difference in the control level of asthma berween the group receiving treatment with regular inhaled corticosteroids (ICS) and the group receiving treatment with irregular ICS (P<0.01). CONCLUSIONS: Bad efficacy, remission of asthma, expensive fees, complex process of treatment, and adverse reaction are the main reasons contributing to the stop of SCIT in asthmatic children. To improve the compliance with SCIT, It is important to make the patients and their parents understand the long treatment course and slow effect of SCIT, encourage them to use objective indices for evaluating the state of asthma, and effectively prevent and treat the adverse reactions.
HUANG Ya-Na,HUANG Ying,DAI Ji-Hong et al. Causes of stopping subcutaneous specific immunotherapy in asthmatic children[J]. 中国当代儿科杂志, 2012, 14(09): 671-674.
HUANG Ya-Na,HUANG Ying,DAI Ji-Hong et al. Causes of stopping subcutaneous specific immunotherapy in asthmatic children[J]. CJCP, 2012, 14(09): 671-674.
［11］Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three yeas of specific immunotherapy may be sufficient in house dust mite respiratory allergy［J］.J Allergy Clin Immunol, 2011, 127(1): 57-63.
［14］Cools M, Van Bever HP, Weylev JJ, Steven WJ. Long-term effect of specific immunotherapy, administered during childhood, in asthmatic patiants allergic to either house-dust mite or to both house-dust mite and grass pollen［J］. Allergy, 2000, 55(1): 69-73.
